Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$115.78
+6.2%
$148.26
$91.86
$254.15
$5.69B1.45915,839 shs2.63 million shs
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$45.60
+3.4%
$45.50
$39.97
$72.83
$8.47B1.142.61 million shs1.25 million shs
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$165.21
$167.50
$93.00
$175.95
$10.70B1.31837,472 shs57 shs
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
$42.86
$22.89
$52.23
$4.46B1.581.92 million shsN/A
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+1.81%+4.33%-34.88%-34.67%-54.60%
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-0.14%+4.33%-6.37%-20.03%-30.60%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00%0.00%0.00%0.00%0.00%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.8327 of 5 stars
4.04.00.04.72.93.31.9
Exact Sciences Co. stock logo
EXAS
Exact Sciences
4.2635 of 5 stars
4.51.00.04.72.81.70.6
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.94
Reduce$182.0057.19% Upside
Exact Sciences Co. stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$69.2551.86% Upside
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00
N/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EXAS, CRL, PRAH, and SYNH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
4/10/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.00
4/10/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.00
4/10/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00
4/9/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.00
4/9/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/28/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00
3/21/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$190.00 ➝ $170.00
3/13/2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Perform$52.00
3/4/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$155.00 ➝ $175.00
3/3/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$188.00
(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.40$15.48 per share7.48$67.80 per share1.71
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$2.76B3.07$5.19 per share8.79$12.93 per share3.53
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$3.18B3.36$6.09 per share27.11$23.06 per share7.16
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$474.62M$0.15771.8710.534.540.52%14.69%6.79%5/7/2025 (Estimated)
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$204.15M-$5.57N/A91.20N/A-37.29%-5.29%-2.45%5/1/2025 (Estimated)
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$197.04M$3.9050.5226.31N/A6.40%20.49%7.07%N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A

Latest EXAS, CRL, PRAH, and SYNH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06N/AN/AN/A$942.34 millionN/A
5/1/2025Q1 2025
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$0.35N/AN/AN/A$688.58 millionN/A
2/19/2025Q4 2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.50$2.66+$0.16-$4.22$983.63 million$1.00 billion
2/19/2025Q4 2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Exact Sciences Co. stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.65
1.41
1.14
Exact Sciences Co. stock logo
EXAS
Exact Sciences
0.97
2.15
1.93
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.74
1.21
1.21
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Exact Sciences Co. stock logo
EXAS
Exact Sciences
88.82%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
93.93%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
91.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
21,40049.12 million50.47 millionOptionable
Exact Sciences Co. stock logo
EXAS
Exact Sciences
6,400185.76 million182.56 millionOptionable
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
18,10064.80 millionN/AOptionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable

Recent News About These Companies

Syneos Health makes senior hires
INC Research/inVentiv Health Becomes Syneos Health
Investment group will take Syneos Health private
Hayward Holdings, Inc. (HAYW)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$115.78 +6.78 (+6.22%)
As of 03:59 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$45.60 +1.51 (+3.42%)
As of 04:00 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

PRA Health Sciences stock logo

PRA Health Sciences NASDAQ:PRAH

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Syneos Health stock logo

Syneos Health NASDAQ:SYNH

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.